{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T18:46:56Z","timestamp":1793213216231,"version":"4.5.0"},"reference-count":96,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2012,7,1]],"date-time":"2012-07-01T00:00:00Z","timestamp":1341100800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2012,7]]},"DOI":"10.1016\/j.clinthera.2012.06.010","type":"journal-article","created":{"date-parts":[[2012,6,28]],"date-time":"2012-06-28T05:16:17Z","timestamp":1340860577000},"page":"1487-1504","source":"Crossref","is-referenced-by-count":166,"title":["Tetrabenazine for the Treatment of Hyperkinetic Movement Disorders: A Review of the Literature"],"prefix":"10.1016","volume":"34","author":[{"given":"Jack J.","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William G.","family":"Ondo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khashayar","family":"Dashtipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Swope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2012.06.010_bib1","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1055\/s-0029-1245005","article-title":"Pearls: hyperkinetic movement disorders","volume":"30","author":"Reich","year":"2010","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib3","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/ncpneuro0617","article-title":"Mechanisms of disease: basic-research-driven investigations in humans\u2014the case of hyperkinetic disorders","volume":"3","author":"Centonze","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"issue":"3","key":"10.1016\/j.clinthera.2012.06.010_bib4","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Systematic Rev"},{"key":"10.1016\/j.clinthera.2012.06.010_bib5","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1055\/s-2007-971169","article-title":"Tardive dyskinesia","volume":"27","author":"Soares-Weiser","year":"2007","journal-title":"Semin Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib6","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1517\/14656560903426171","article-title":"Treatment strategies for dystonia","volume":"11","author":"Cloud","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2012.06.010_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.2147\/NDT.S12990","article-title":"Update on the role of antipsychotics in the treatment of Tourette syndrome","volume":"8","author":"Huys","year":"2012","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2012.06.010_bib8","doi-asserted-by":"crossref","first-page":"2883","DOI":"10.1517\/14656560903386292","article-title":"Tetrabenazine","volume":"10","author":"Fasano","year":"2009","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2012.06.010_bib9","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.2165\/11208330-000000000-00000","article-title":"Tetrabenazine: for chorea associated with Huntington's disease","volume":"25","author":"Scott","year":"2011","journal-title":"CNS Drugs"},{"key":"10.1016\/j.clinthera.2012.06.010_bib10","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1586\/ern.11.149","article-title":"Tetrabenazine for the treatment of chorea and other hyperkinetic movement disorders","volume":"11","author":"Jankovic","year":"2011","journal-title":"Expert Rev Neurother"},{"key":"10.1016\/j.clinthera.2012.06.010_bib11","doi-asserted-by":"crossref","first-page":"123","DOI":"10.2147\/TCRM.S17152","article-title":"Management of Huntington's disease: role of tetrabenazine","volume":"7","author":"de Tommaso","year":"2011","journal-title":"Ther Clin Risk Manag"},{"key":"10.1016\/j.clinthera.2012.06.010_bib12","doi-asserted-by":"crossref","first-page":"657","DOI":"10.2147\/NDT.S6430","article-title":"Tetrabenazine: the first approved drug for the treatment of chorea in US patients with Huntington disease","volume":"6","author":"Frank","year":"2010","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.clinthera.2012.06.010_bib13","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1345\/aph.1M582","article-title":"Role of tetrabenazine for Huntington's disease-associated chorea","volume":"44","author":"Poon","year":"2010","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2012.06.010_bib14","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1345\/aph.1P312","article-title":"Tetrabenazine for the treatment of tardive dyskinesia","volume":"45","author":"Leung","year":"2011","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2012.06.010_bib15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.amjopharm.2010.08.006","article-title":"Tetrabenazine, a monoamine-depleting drug used in the treatment of hyperkinetic movement disorders","volume":"8","author":"Guay","year":"2010","journal-title":"Am J Geriatr Pharmacother"},{"key":"10.1016\/j.clinthera.2012.06.010_bib16","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/BF00615962","article-title":"The pharmacokinetics of tetrabenazine and its hydroxy metabolite in patients treated for involuntary movement disorders","volume":"29","author":"Roberts","year":"1986","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib17","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1016\/j.ejmech.2011.02.046","article-title":"Preparation and evaluation of tetrabenazine enantiomers and all eight stereoisomers of dihydrotetrabenazine as VMAT2 inhibitors","volume":"46","author":"Yao","year":"2011","journal-title":"Eur J Med Chem"},{"key":"10.1016\/j.clinthera.2012.06.010_bib18","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/S0090-9556(25)06690-5","article-title":"Pharmacokinetics of tetrabenazine and its major metabolite in man and rat","volume":"15","author":"Mehvar","year":"1987","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2012.06.010_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/10409238709082546","article-title":"Mechanism of storage and transport of neurotransmitters","volume":"22","author":"Kanner","year":"1987","journal-title":"CRC Crit Rev Biochem"},{"key":"10.1016\/j.clinthera.2012.06.010_bib20","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1152\/physrev.1988.68.1.232","article-title":"Accumulation of biological amines into chromaffin granules: a model for hormone and neurotransmitter transport","volume":"68","author":"Johnson","year":"1988","journal-title":"Physiol Rev"},{"key":"10.1016\/j.clinthera.2012.06.010_bib21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/med.20187","article-title":"Vesicular monoamine transporters: structure-function, pharmacology, and medicinal chemistry","volume":"31","author":"Wimalasena","year":"2011","journal-title":"Med Res Rev"},{"key":"10.1016\/j.clinthera.2012.06.010_bib22","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1111\/j.1471-4159.1993.tb03521.x","article-title":"In vivo imaging of vesicular monoamine transporters in human brain using [11C]tetrabenazine and positron emission tomography","volume":"60","author":"Kilbourn","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/j.clinthera.2012.06.010_bib23","first-page":"2252","article-title":"In vivo imaging of the brain vesicular monoamine transporter","volume":"36","author":"Vander Borght","year":"1995","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clinthera.2012.06.010_bib24","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1097\/00004647-199912000-00011","article-title":"Assessment of extrastriatal vesicular monoamine transporter binding site density using stereoisomers of [11C]dihydrotetrabenazine","volume":"19","author":"Koeppe","year":"1999","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.clinthera.2012.06.010_bib25","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1097\/00004647-199709000-00001","article-title":"Equilibrium versus compartmental analysis for assessment of the vesicular monoamine transporter using (+)-alpha-[11C]dihydrotetrabenazine (DTBZ) and positron emission tomography","volume":"17","author":"Koeppe","year":"1997","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.clinthera.2012.06.010_bib26","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/0028-3908(88)90080-9","article-title":"Depletion of monoamine transmitters by tetrabenazine in brain tissue in Huntington's disease","volume":"27","author":"Pearson","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib27","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2165\/00044011-200828070-00006","article-title":"Tourette's syndrome and role of tetrabenazine","volume":"28","author":"Porta","year":"2008","journal-title":"Clin Drug Invest"},{"key":"10.1016\/j.clinthera.2012.06.010_bib28","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S0074-7742(08)60024-0","article-title":"Benzoquinolizine derivatives: a new class of monamine decreasing drugs with psychotropic action","volume":"4","author":"Pletscher","year":"1962","journal-title":"Rev Neurobiol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib29","first-page":"267","article-title":"Long-term treatment of tardive dyskinesia with presynaptically acting dopamine-depleting agents","volume":"37","author":"Fahn","year":"1983","journal-title":"Adv Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib30","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/S1474-4422(06)70494-X","article-title":"Seminar on choreas","volume":"5","author":"Cardoso","year":"2006","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib31","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1212\/WNL.33.10.1268","article-title":"Abnormal ocular motor control in Huntington's disease","volume":"33","author":"Leigh","year":"1983","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib32","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1002\/mds.870080216","article-title":"Adult onset myoclonic Huntington's disease","volume":"8","author":"Carella","year":"1993","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib33","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/mds.870100116","article-title":"Tourettism associated with Huntington's disease","volume":"10","author":"Jankovic","year":"1995","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib34","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1531-8257(200001)15:1<171::AID-MDS1031>3.0.CO;2-Y","article-title":"Bruxism in Huntington's disease","volume":"15","author":"Tan","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib35","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/1531-8257(199901)14:1<95::AID-MDS1016>3.0.CO;2-8","article-title":"Dystonia in Huntington's disease: prevalence and clinical characteristics","volume":"14","author":"Louis","year":"1999","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib36","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1002\/mds.22003","article-title":"Falls and gait disturbances in Huntington's disease","volume":"23","author":"Grimbergen","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib37","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1176\/ajp.140.6.728","article-title":"Psychiatric syndromes in Huntington's disease","volume":"140","author":"Caine","year":"1983","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib38","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1136\/jnnp.47.12.1283","article-title":"Increased rate of suicide among patients with Huntington's disease","volume":"47","author":"Schoenfeld","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib39","doi-asserted-by":"crossref","first-page":"189","DOI":"10.2190\/HU6W-3K7Q-NAEL-XU6K","article-title":"Huntington's disease: update and review of neuropsychiatric aspects","volume":"24","author":"Mendez","year":"1994","journal-title":"Int J Psychiatry Med"},{"key":"10.1016\/j.clinthera.2012.06.010_bib40","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1600-0447.1994.tb01587.x","article-title":"Psychopathology in Huntington's disease patients","volume":"90","author":"Shiwach","year":"1994","journal-title":"Acta Psychiatr Scand"},{"key":"10.1016\/j.clinthera.2012.06.010_bib41","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/S0033-3182(00)71170-4","article-title":"Neuropsychiatry of Huntington's disease and other basal ganglia disorders","volume":"41","author":"Rosenblatt","year":"2000","journal-title":"Psychosomatics"},{"issue":"Pt 5","key":"10.1016\/j.clinthera.2012.06.010_bib42","doi-asserted-by":"crossref","first-page":"1633","DOI":"10.1093\/brain\/119.5.1633","article-title":"Executive and mnemonic functions in early Huntington's disease","volume":"119","author":"Lawrence","year":"1996","journal-title":"Brain"},{"key":"10.1016\/j.clinthera.2012.06.010_bib43","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1001\/archneur.58.2.273","article-title":"Progression of symptoms in the early and middle stages of Huntington disease","volume":"58","author":"Kirkwood","year":"2001","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib44","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/01.WNL.0000098878.47789.BD","article-title":"Profile of cognitive progression in early Huntington's disease","volume":"61","author":"Ho","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib45","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1001\/archneur.1988.00520320068017","article-title":"Conditions associated with Huntington's disease at death","volume":"45","author":"Lanska","year":"1988","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib46","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1136\/jmg.29.12.911","article-title":"Causes of death in patients with Huntington's disease and in unaffected first degree relatives","volume":"29","author":"Sorensen","year":"1992","journal-title":"J Med Genet"},{"key":"10.1016\/j.clinthera.2012.06.010_bib47","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/0092-8674(93)90585-E","article-title":"A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes","volume":"72","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.clinthera.2012.06.010_bib48","first-page":"16","article-title":"Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats","volume":"59","author":"Rubinsztein","year":"1996","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2012.06.010_bib49","first-page":"593","article-title":"Anticipation and instability of IT-15 (CAG)n repeats in parent-offspring pairs with Huntington disease","volume":"57","author":"Ranen","year":"1995","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.clinthera.2012.06.010_bib50","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1212\/WNL.53.4.801","article-title":"DNA analysis of Huntington's disease: five years of experience in Germany, Austria, and Switzerland","volume":"53","author":"Laccone","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib51","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1002\/mds.21195","article-title":"Autopsy-proven Huntington's disease with 29 trinucleotide repeats","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib52","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1126\/science.2931802","article-title":"Selective sparing of a class of striatal neurons in Huntington's disease","volume":"230","author":"Ferrante","year":"1985","journal-title":"Science"},{"key":"10.1016\/j.clinthera.2012.06.010_bib53","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/0304-3940(91)90583-F","article-title":"Neuronal loss in layers V and VI of cerebral cortex in Huntington's disease","volume":"133","author":"Hedreen","year":"1991","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.clinthera.2012.06.010_bib54","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1373\/49.10.1726","article-title":"Diagnosis of Huntington disease","volume":"49","author":"Margolis","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.clinthera.2012.06.010_bib55","doi-asserted-by":"crossref","first-page":"4252","DOI":"10.1111\/j.1742-4658.2008.06561.x","article-title":"Huntington's disease: revisiting the aggregation hypothesis in polyglutamine neurodegenerative diseases","volume":"275","author":"Truant","year":"2008","journal-title":"FEBS J"},{"key":"10.1016\/j.clinthera.2012.06.010_bib56","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington's disease: an evidence based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.clinthera.2012.06.010_bib57","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1517\/14656566.8.2.141","article-title":"A systematic review of the treatment studies in Huntington's disease since 1990","volume":"8","author":"Bonelli","year":"2007","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.clinthera.2012.06.010_bib58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.2165\/11534430-000000000-00000","article-title":"Advances in the pharmacological management of Huntington's disease","volume":"70","author":"Frank","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.clinthera.2012.06.010_bib59","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib60","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/WNF.0b013e3180ca77ea","article-title":"A study of chorea after tetrabenazine withdrawal in patients with Huntington's disease","volume":"31","author":"Frank","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib61","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/1471-2377-9-62","article-title":"Tetrabenazine as anti-chorea therapy in Huntington disease: an open-label continuation study","volume":"9","author":"Frank","year":"2009","journal-title":"BMC Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib62","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/mds.22376","article-title":"Treatment of the symptoms of Huntington's disease: preliminary results comparing aripiprazole and tetrabenazine","volume":"24","author":"Brusa","year":"2009","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1002\/mds.21161","article-title":"Short-term effects of tetrabenazine on chorea associated with Huntington's disease","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib64","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1097\/WNF.0b013e318166da60","article-title":"The long-term effect of tetrabenazine in the management of Huntington's disease: observational study","volume":"31","author":"Fasano","year":"2008","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib65","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/mds.21222","article-title":"Long-term tolerability of tetrabenazine in the treatment of hyperkinetic movement disorders","volume":"22","author":"Kenney","year":"2007","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.parkreldis.2012.04.029","article-title":"Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients","author":"Fekete","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib67","article-title":"Dystonia","volume":"2011","author":"Snaith","year":"2011","journal-title":"Clin Evid (Online)"},{"key":"10.1016\/j.clinthera.2012.06.010_bib68","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1136\/jnnp.35.2.186","article-title":"Treatment of involuntary movement disorders with tetrabenazine","volume":"35","author":"Swash","year":"1972","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib69","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1212\/WNL.31.8.1051","article-title":"Tetrabenazine and movement disorders","volume":"31","author":"Asher","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib70","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1002\/ana.410110108","article-title":"Treatment of hyperkinetic movement disorders with tetrabenazine: a double-blind crossover study","volume":"11","author":"Jankovic","year":"1982","journal-title":"Ann Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib71","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1136\/jnnp.47.11.1166","article-title":"The treatment of severe dystonia in children and adults","volume":"47","author":"Marsden","year":"1984","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib72","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1212\/WNL.38.3.391","article-title":"Tetrabenazine therapy of dystonia, chorea, tics and other dyskinesia","volume":"38","author":"Jankovic","year":"1988","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib73","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1212\/WNL.48.2.358","article-title":"Long-term effects of tetrabenazine in hyperkinetic movement disorders","volume":"48","author":"Jankovic","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2012.06.010_bib74","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1097\/01.wnf.0000136892.24629.96","article-title":"Tetrabenazine treatment in movement disorders","volume":"27","author":"Paleacu","year":"2004","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib75","series-title":"Drug-Induced Diseases: Prevention, Detection, and Management","first-page":"211","article-title":"Movement disorders","author":"Chen","year":"2010"},{"key":"10.1016\/j.clinthera.2012.06.010_bib76","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/bmj.4.5778.25","article-title":"Persistent phenothiazine dyskinesia treated with tetrabenazine","volume":"4","author":"Godwin-Austen","year":"1971","journal-title":"Br Med J"},{"key":"10.1016\/j.clinthera.2012.06.010_bib77","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1001\/archpsyc.1972.01750250081011","article-title":"Treatment of tardive dyskinesia: clinical efficacy of a dopamine-depleting agent, tetrabenazine","volume":"27","author":"Kazamatsuri","year":"1972","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib78","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1176\/ajp.130.4.479","article-title":"Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine","volume":"130","author":"Kazamatsuri","year":"1973","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib79","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1177\/070674378803300104","article-title":"Treatment of tardive dyskinesia: preliminary report on use of tetrabenazine","volume":"33","author":"Watson","year":"1988","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib80","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1176\/ajp.156.8.1279","article-title":"Tetrabenazine treatment for tardive dyskinesia: assessment by randomized videotape protocol","volume":"156","author":"Ondo","year":"1999","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib82","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/S0079-6123(08)00924-2","article-title":"Neurobiological basis of serotonin-dopamine antagonists in the treatment of Gilles de la Tourette syndrome","volume":"172","author":"Steeves","year":"2008","journal-title":"Prog Brain Res"},{"key":"10.1016\/j.clinthera.2012.06.010_bib83","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1001\/archpsyc.1974.01760180095012","article-title":"Presynaptic catecholamine antagonists as treatment for Tourette syndrome","volume":"31","author":"Sweet","year":"1974","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.clinthera.2012.06.010_bib84","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1212\/WNL.34.5.688","article-title":"Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome","volume":"34","author":"Jankovic","year":"1984","journal-title":"Neurology"},{"issue":"Suppl 3","key":"10.1016\/j.clinthera.2012.06.010_bib85","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1017\/S0317167100038087","article-title":"Motor, behavioral and pharmacologic findings in Tourette's syndrome","volume":"14","author":"Jankovic","year":"1987","journal-title":"Can J Neurol Sci"},{"issue":"Suppl 9","key":"10.1016\/j.clinthera.2012.06.010_bib86","first-page":"S422","article-title":"Safety and efficacy of tetrabenazine in childhood hyperkinetic movement disorders","volume":"19","author":"Vuong","year":"2004","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib87","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1002\/mds.21063","article-title":"Tetrabenazine therapy of pediatric hyperkinetic movement disorders","volume":"21","author":"Jain","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib88","first-page":"9","article-title":"Tetrabenazine in the treatment of Tourette's syndrome","volume":"5","author":"Kenney","year":"2007","journal-title":"J Ped Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib89","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1001\/archneur.1986.00520100039012","article-title":"Segmental myoclonus","volume":"43","author":"Jankovic","year":"1986","journal-title":"Arch Neurol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib90","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/mds.21100","article-title":"Tetrabenazine (TBZ) for hyperglycemic-induced hemichorea-hemiballismus (HIHH)","volume":"21","author":"Sitburana","year":"2006","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib91","unstructured":"Ondo WG. Tetrabenazine treatment for stereotypies and tics associated with dementia. J Neuropsych Clin Neurosci. In press."},{"key":"10.1016\/j.clinthera.2012.06.010_bib92","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/00002826-199202000-00009","article-title":"Neuroleptic malignant syndrome related to tetrabenazine introduction and haloperidol discontinuation in Huntington's disease","volume":"15","author":"Mateo","year":"1992","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib93","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1002\/mds.870110118","article-title":"Tetrabenazine as a cause of neuroleptic malignant syndrome","volume":"11","author":"Ossemann","year":"1996","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib94","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/mds.870120219","article-title":"A case of tetrabenazine-induced neuroleptic malignant syndrome after prolonged treatment","volume":"12","author":"Petzinger","year":"1997","journal-title":"Mov Disord"},{"key":"10.1016\/j.clinthera.2012.06.010_bib95","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s001340050583","article-title":"Severe hyperthermia during tetrabenazine therapy for tardive dyskinesia","volume":"24","author":"Stevens","year":"1998","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.clinthera.2012.06.010_bib97","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1097\/01.WNF.0000228369.25593.35","article-title":"Is history of depression a contraindication to treatment with tetrabenazine","volume":"29","author":"Kenney","year":"2006","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.clinthera.2012.06.010_bib98","doi-asserted-by":"crossref","first-page":"RRN1283","DOI":"10.1371\/currents.RRN1283","article-title":"Use of tetrabenazine in Huntington disease patients on antidepressants or with advanced disease: results from the TETRA-HD study","volume":"3","author":"Dorsey","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.clinthera.2012.06.010_bib99","series-title":"RED BOOK Online. Micromedex 2.0","author":"Xenazine","year":"2012"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003736?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291812003736?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T20:49:10Z","timestamp":1743626950000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291812003736"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,7]]},"references-count":96,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2012,7]]}},"alternative-id":["S0149291812003736"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2012.06.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2012,7]]}}}